Skip to main content
News Icon

News categories: Publication

CRC for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Prof. Dr. med. Alexander Pfeifer becomes speaker of the newly founded Collaborative Research Center for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Worldwide, the number of overweight and obese patients is increasing, and consequently diabetes and cardiovascular disease. Obesity is also a risk factor for developing severe Covid19. In the Transregional Collaborative Research Centre (CRC) 333 "Brown and Beige Fat Organ Crosstalk, Signaling and Energetics ( BATenergy)", researchers from the University of Bonn and the University Hospital Bonn, the University Medical Center Hamburg-Eppendorf (UKE), the Technical University of Munich (TUM) and the Helmholtz Zentrum München are investigating different types of adipose tissue and their role in metabolic diseases. As speaker of the CRC, Prof. Dr. med. Alexander Pfeifer, member of ImmunoSensation2 and head of the institute of Pharmacology and Toxicology at the University Clinics Bonn, was appointed.

The CRC’s research focus lies on brown fat cells, which are specialized in converting energy into heat. This makes them fundamentally different from white fat cells, which store energy in the form of fat. But even in white adipose tissue there are isolated brown fat cells, called "beige" cells. The goal of the CRC is to characterize the function of brown adipose cells at all levels, to uncover new communication pathways within our body, and thus to develop new therapeutic approaches for metabolic diseases in the future.

Brown adipose tissue is activated by cold. The researchers want to identify the body's own messenger substances and find out how different organs regulate brown fat. "This will provide a new picture of mutual communication of adipose tissue with other metabolic organs," says Prof. Dr. Alexander Pfeifer.

In their projects, the teams use state-of-the-art molecular biology methods as well as cell culture systems of fat cells and investigate metabolism from mice to humans. In this way, they hope to uncover new molecular mechanisms and target structures for drugs. On the long term, this should lead to new therapeutic approaches for the treatment of metabolic disease.

The vice speakers Prof. Dr. Jörg Heeren from the Institute of Biochemistry and Molecular Cell Biology of the UKE and Prof. Dr. Henriette Uhlenhaut from the TUM School of Life Sciences emphasize that the CRC uniquely brings together expert teams from metabolism research at three German Universities of Excellence and the Helmholtz Zentrum in Munich.

The CRC is thematically embedded in the Transdisciplinary Research Areas "Life and Health" and "Sustainable Futures" of the University of Bonn. At the UKE, the CRC is thematically assigned to the interdisciplinary research area C3I (Center for Inflammation, Infection and Immunity).

Contact

Prof. Dr. med. Alexander Pfeifer

Institute of Pharmacology and Toxicology

University of Bonn

Phone: +49-228-287-51300/51302

Email: alexander.pfeifer@uni-bonn.de

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview